Hematological Neoplasms
Breaking Barriers: Equecabtagene Autoleucel Revives Hope for International RRMM Patients – Multiple Myeloma Relapsed/refractory multiple myeloma (RRMM) presents a significant challenge worldwide, representing 13% of all blood cancers. Despite advances in treatment, many patients face poor outcomes and limited options. However, a groundbreaking CAR-T therapy, Equecabtagene Autoleucel, has recently demonstrated its life-changing potential in overcoming Read More
**Groundbreaking Results for Chinese CAR-T Therapy: 86% Response Rate of BCMA/GPRC5D Dual-Target Treatment** #MultipleMyeloma #ChineseCART #BCMA #GPRC5D #DualTarget #MM #RRMM Multiple myeloma (MM) is a challenging blood cancer, particularly in relapsed/refractory (R/R) cases. While therapies like proteasome inhibitors, immunomodulators, CD38 monoclonal antibodies, and stem cell transplants have improved outcomes for newly diagnosed patients, treatment-resistant forms Read More
Redefining Hope for High-Risk RRMM Patients Worldwide: A Singaporean Patient`s Journey to China for Groundbreaking CAR-T Therapy #MultipleMyeloma #CAR_Therapy #CancerTreatment #HRMM #MM #RRMM #CART In the fight against multiple myeloma (MM), the last few decades have seen significant advancements, yet the disease remains notoriously difficult to cure, particularly in patients with relapsed/refractory multiple myeloma (RRMM). Read More
On July 24, 2020, the FDA approved Tecatus for the treatment of relapsed/refractory mantle cell lymphoma (MCL) in adult patients, It is the first and only CAR-T therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory mantle cell lymphoma (R/R MCL) in adult patients.